NCT06772532

A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body

Relative Bioavailability of Three Different BI 456906 Formulations Following Subcutaneous Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Trial)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main objective of this trial is to investigate relative bioavailability of BI 456906 formulation B and BI 456906 formulation C vs. BI 456906 formulation A.

Conditions

• Healthy

Interventions

Type	Name	Description
COMBINATION_PRODUCT	BI 456906 - Formulation A	Formulation A
DRUG	BI 456906 - Formulation B	Formulation B
DRUG	BI 456906 - Formulation C	Formulation C

Timeline

• Start date: 2025-02-10
• Primary completion: 2025-05-29
• Completion: 2025-06-10
• First posted: 2025-01-13
• Last updated: 2026-03-13

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study